Navigation Links
Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
Date:9/17/2007

ase inhibitor boosted by ritonavir and at least two drugs that are active, based on susceptibility testing. The optimized background therapy will be chosen by the investigator based on results of drug susceptibility tests performed at screening, patient history of prior antiretroviral drug use and drug toxicity.

The VICTOR-E3 and VICTOR-E4 studies will also evaluate the safety and tolerability of vicriviroc compared to placebo, each given in combination with an optimized background therapy. An independent, external Data Safety Monitoring Board (DSMB) will review study data on a regular basis to assure continued safety of the participants.

For more information about the VICTOR-E3 and VICTOR-E4 clinical studies, please visit http://www.clinicaltrials.gov, search term: vicriviroc.

About Schering-Plough

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the timing of clinical trials, the company's plans and the potential for vicriviroc. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
4. Malvern initiates European user group meetings for chemical imaging
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia ... interim clinical data for its lead candidate ITCA 650 ... patients with high baseline HbA1c levels at the 50 ... the Study of Diabetes (EASD). Data from the open-label, ... levels of blood sugar in patients with poorly controlled ...
(Date:9/19/2014)... BALTIMORE and CAMBRIDGE, Mass. ... Diagnostics Inc. (PGDx), a provider of advanced ... Blueprint Medicines , a leader in discovering and ... cancers, today disclosed the first-ever comprehensive genomic study ... and deadly cancer of the female reproductive system, ...
(Date:9/19/2014)... 19, 2014  PCI is pleased to announce ... is a leading provider of Clinical Trial Services ... Wales in the ... expands PCI,s presence in the UK/EU to support ... packaging, storage and distribution capacity, as well as ...
Breaking Medicine Technology:Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
... April 23, 2007 /PRNewswire-FirstCall/,Micromet, Inc. today announced ... collaboration with MedImmune, Inc. for the development,of ... validated tumor- associated antigen frequently expressed on,various ... 2007 Annual Meeting of the American Association ...
... 23, 2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:AOLS) announced ... Linda University Medical Center showing,that one of ... an important role regulating the oxidative damage,induced ... alone or in combination with surgery,and chemotherapy ...
Cached Medicine Technology:Micromet Achieves Milestone in BiTE Research Collaboration with,MedImmune 2Micromet Achieves Milestone in BiTE Research Collaboration with,MedImmune 3Micromet Achieves Milestone in BiTE Research Collaboration with,MedImmune 4Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role,Regulating the Oxidative Damage Induced by Ionizing Radiation 2Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role,Regulating the Oxidative Damage Induced by Ionizing Radiation 3
(Date:9/19/2014)... 19, 2014 Lipitor lawsuits ( http://www.thelipitorlawsuit.com/ ... patients to develop Type 2 diabetes continue to move ... U.S. District Court, District of South Carolina, Bernstein Liebhard ... September 12, 2014, discovery is underway and moving forward ... that Pfizer, Inc., the manufacturer of Lipitor, has produced ...
(Date:9/19/2014)... 2014 In partnership with Raw Beauty NYC, ... part of the project’s social media efforts. StudioPMG is honored ... re-define the perception of beauty as it applies to disabled ... idea by Shelly Baer and Vanessa Silberman, who wanted to ... and beautiful. Ginny Dixon, Wendy Crawford, Susan Solman and Sabrina ...
(Date:9/19/2014)... Fla. Researchers at Jacksonville,s campus of Mayo Clinic ... they say contributes to both overproduction of toxic protein ... as well as loss of communication between neurons ... Their study, in the online issue of ... specific defect with drugs "may rejuvenate or rescue this ...
(Date:9/19/2014)... states are passing legislation permitting or requiring schools to ... having a severe allergic reaction. Epinephrine auto-injectors are ... can lead to throat swelling, breathing difficulties, a steep ... In people with severe allergies to certain foods, such ... drugs, anaphylaxis can occur within moments of exposure to ...
(Date:9/19/2014)... and large protein complexes are notoriously difficult to study ... very difficult, if not impossible, to crystallize, but also ... The result is that when a structure can be ... reveals a mosaic-like spread of protein domains that sometimes ... Brunger. (2014), Acta Cryst . D70, 2241-2255; ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 3Health News:A refined approach to proteins at low resolution 2Health News:A refined approach to proteins at low resolution 3
... from 12 Days to 27 Hours , ... leading provider of Windows file server virtualization solutions, today ... for medical research and treatment, has deployed its AutoClone(TM) ... of its Windows data replication operations. Since its ...
... line to provide sun protection, laughs and college ... Today non-profit Cancer for College launches a ... All proceeds from the sunscreen sales will go ... in granting college scholarships to cancer survivors and ...
... COM,VANCOUVER, May 19 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: ... period under the Hart-Scott-Rodino Act for the collaboration and ... Merck affiliate for development and commercialization of vernakalant, an ... expired, and the agreement is now effective. , Under ...
... say the disease is no more dangerous than regular ... World Health Organization may declare a full-fledged swine flu ... has swept through Japan, a former WHO infectious disease ... occurring in a region outside North America, where a ...
... plating system offers zero-step locking mechanismHOFFMAN ESTATES, Ill., ... market introduction of the KINETIC-SL Dynamic Anterior Cervical ... from the U.S. Food and Drug Administration (FDA) ... cervical plating system and utilizes a ...
... DIEGO, May 19 /PRNewswire/ -- ... major advances in the development of their first-in-class, CK2 ... Wednesday, May 20th at 4:40 pm. William G. Rice, ... antitumor properties and tumor selectivity of CX-4945, the Company,s ...
Cached Medicine News:Health News:Children's Hospital Boston Deploys AutoVirt Solution to Increase Speed and Efficiency of Windows Data Replication 2Health News:Children's Hospital Boston Deploys AutoVirt Solution to Increase Speed and Efficiency of Windows Data Replication 3Health News:Children's Hospital Boston Deploys AutoVirt Solution to Increase Speed and Efficiency of Windows Data Replication 4Health News:Photos: Will Ferrell Sunscreen to Launch Just in Time for Summer 2Health News:Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective 2Health News:Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective 3Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 2Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 3Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 4Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 5Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 6Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 7Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 8Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 9Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 10Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 11Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 12Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 13Health News:Cylene to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at BIO Conference 2